OTCMKTS:INVVYINDIVIOR PLC/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding INDIVIOR PLC/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.90 +0.53 (+12.13 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$3.82Now: $4.90▼$6.1050-Day Range$2.80MA: $4.53▼$11.2052-Week Range$2.23Now: $4.90▼$40.00Volume76,789 shsAverage Volume126,444 shsMarket Capitalization$717.79 millionP/E RatioN/ADividend YieldN/ABeta0.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for INDIVIOR PLC/S. Previous Next 1.9 Community Rank Outperform VotesINDIVIOR PLC/S has received 116 “outperform” votes. (Add your “outperform” vote.)Underperform VotesINDIVIOR PLC/S has received 191 “underperform” votes. (Add your “underperform” vote.)Community SentimentINDIVIOR PLC/S has received 62.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about INDIVIOR PLC/S and other stocks. Vote “Outperform” if you believe INVVY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INVVY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldINDIVIOR PLC/S does not currently pay a dividend.Dividend GrowthINDIVIOR PLC/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, INDIVIOR PLC/S insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of INDIVIOR PLC/S is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INDIVIOR PLC/S is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINDIVIOR PLC/S has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.38 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INVVY Previous SymbolNASDAQ:INVVY CUSIPN/A CIKN/A Webwww.indivior.com Phone804-379-1090Debt Debt-to-Equity Ratio1.36 Current Ratio1.83 Quick Ratio1.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$785 million Price / Sales0.91 Cash Flow$1.38 per share Price / Cash Flow3.56 Book Value$1.43 per share Price / Book3.43Profitability EPS (Most Recent Fiscal Year)$1.15 Net Income$134 million Net Margins-13.57% Return on Equity37.84% Return on Assets5.24%Miscellaneous Employees915 Outstanding Shares146,487,000Market Cap$717.79 million Next Earnings Date7/29/2020 (Estimated) OptionableNot Optionable OTC:INVVY Rates by TradingView Receive INVVY News and Ratings via Email Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter. INDIVIOR PLC/S (OTCMKTS:INVVY) Frequently Asked Questions How has INDIVIOR PLC/S's stock been impacted by COVID-19 (Coronavirus)? INDIVIOR PLC/S's stock was trading at $2.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INVVY shares have increased by 72.5% and is now trading at $4.90. View which stocks have been most impacted by Coronavirus. When is INDIVIOR PLC/S's next earnings date? INDIVIOR PLC/S is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for INDIVIOR PLC/S. Has INDIVIOR PLC/S been receiving favorable news coverage? News coverage about INVVY stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. INDIVIOR PLC/S earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutINDIVIOR PLC/S. Who are some of INDIVIOR PLC/S's key competitors? Some companies that are related to INDIVIOR PLC/S include Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB) and Pacira Biosciences (PCRX). View all competitors. Who are INDIVIOR PLC/S's key executives? INDIVIOR PLC/S's management team includes the following people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations What is INDIVIOR PLC/S's stock symbol? INDIVIOR PLC/S trades on the OTCMKTS under the ticker symbol "INVVY." How do I buy shares of INDIVIOR PLC/S? Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is INDIVIOR PLC/S's stock price today? One share of INVVY stock can currently be purchased for approximately $4.90. How big of a company is INDIVIOR PLC/S? INDIVIOR PLC/S has a market capitalization of $717.79 million and generates $785 million in revenue each year. The company earns $134 million in net income (profit) each year or $1.15 on an earnings per share basis. INDIVIOR PLC/S employs 915 workers across the globe. What is INDIVIOR PLC/S's official website? The official website for INDIVIOR PLC/S is www.indivior.com. How can I contact INDIVIOR PLC/S? INDIVIOR PLC/S's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
